Tina Shih is a Neurology physician affiliated with University of California, San Francisco. OpenAlex indexes 23 publications with 1,688 citations (h-index 11).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingMedicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
95.6%Other antiepileptics23.3%Levetiracetam51%Topiramate15%Lacosamide10%Keppra8%Briviact5%Epidiolex5%Vimpat4%Topamax2%Xcopri1%Part D<11 patientsMood Stabilizer22.8%Lamotrigine57%Carbamazepine Er17%Lamotrigine Er10%Lamictal7%Lamictal Xr5%Carbatrol2%Tegretol Xr2%Part D<11 patients+ 13 more classes in this area
Cardiovascular
1.4%Central alpha-2 Adrenergic Agonist1.1%Guanfacine Hcl56%Clonidine Hcl23%Clonidine Hcl Er21%Part D<11 patientsOmega-3 / fibrate0.3%Omega-3 Acid Ethyl Esters100%Part D<11 patientsMetabolism & gastrointestinal
0.9%H2 blocker0.4%Famotidine100%Part D<11 patientsSerotonin-3 Receptor Antagonist0.3%Ondansetron Odt100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2023–2023 per NIH RePORTER. The latest:
- Targeted Oral Anticancer Agents: Patterns of Indicated and Off-Label Use, the Associated Factors and Economic Implications
University of California Los Angeles
FY2023$278,472R01CA225647
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Epilepsy surgery as a treatment option for select patients with PCDH19-related epilepsy
Epilepsy & Behavior
2023 - Intact speech perception after resection of dominant hemisphere primary auditory cortex for the treatment of medically refractory epilepsy: illustrative case
Journal of Neurosurgery Case Lessons
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Emmanuelle Waubant, MD
University of California, San Francisco
Peter Ganz, MD
University of California, San Francisco
Joel Palefsky, MD
University of California, San Francisco
Peter Hunt, MD
University of California, San Francisco
Bruce Miller, MD
University of California, San Francisco (UCSF)
Bradley Boeve, MD
Mayo Clinic
Richard Lipton, MD
Albert Einstein College of Medicine
Steven Dekosky, MD
University of Florida Health
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”